{{NoteTA
|G1=ME
|1=zh-cn:mRNA;zh-hk:信使核糖核酸;zh-tw:信使核糖核酸;
|2=zh-cn:首席执行官;zh-hk:行政總裁;zh-tw:執行長;zh-mo:行政總裁;
}}
{{Infobox company
| name = 莫德纳<br>Moderna, Inc.
| logo = Moderna logo.svg
| logo_size = 200px
| image = Moderna Headquarters, December 2020.jpg
| image_caption = 莫德纳總部，位於馬薩諸塞州劍橋
| type = [[上市公司|上市公司]]
| traded_as = {{ubl|{{NASDAQ|MRNA}}|[[納斯達克100指數|納斯達克100指數]]成分股}}
| former_name = ModeRNA Therapeutics<br />(2010–2018)
| foundation = {{start date and age|2010|9|1}}
| founder = {{ubl|[[德里克·罗西|德里克·罗西]] (創建者)|{{link-en|提摩西·A·斯普林格|Timothy A. Springer}} (投資者)|[[羅伯特·蘭格|羅伯特·蘭格]] (投資者)| {{link-en|肯内特·R·奇恩|Kenneth R. Chien}} (投資者) | Noubar Afeyan (投資者) | Flagship Pioneering (投資者)}}
| location = {{美國}}<ref name=KF/><br>[[马萨诸塞州|马萨诸塞州]][[剑桥_(马萨诸塞州)|剑桥]] 02139<br>200 {{link-en|科技广场 (馬薩諸塞州劍橋)|Technology Square (Cambridge, Massachusetts)|技术广场}}
| industry         = [[制药|制药]]<br>[[生物技术|生物技术]]<br />[[醫療衛生|醫療保健]]
| products = [[疫苗|疫苗]]、[[药品|药品]]
| revenue = 
| num_employees = 820 (2019年12月)<ref name=KF>{{cite website|url=https://www.modernatx.com/about-us/moderna-facts|title=Key Facts|website=Moderna|accessdate=19 May 2020|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154211/https://www.modernatx.com/about-us/moderna-facts|dead-url=no}}</ref>
| website = {{URL|modernatx.com}}
}}  

'''莫德纳'''（{{lang-en|Moderna}}），是一家总部位于[[美国|美国]][[马萨诸塞州|马萨诸塞州]][[剑桥_(马萨诸塞州)|剑桥市]]的跨國[[制药|制药]]、[[生物技术|生物技术]]公司，專注於[[癌症免疫治療|癌症免疫治療]]，包括基於[[信使核糖核酸|信使核糖核酸]]的{{Link-en|藥物發現|Drug discovery}}、[[藥物研發|藥物研發]]和[[疫苗|疫苗]]技術<ref name="BioWorld">{{Cite web|title=Moderna Makes Entrance with $40M Round for mRNA Work|url=http://www.bioworld.com/content/moderna-makes-entrance-40m-round-mrna-work|accessdate=Dec 11, 2013|author=Catherine Shaffer|date=December 6, 2013|publisher=BioWorld|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154313/https://www.bioworld.com/articles/355400-moderna-makes-entrance-with-40m-round-for-mrna-work?v=preview|dead-url=no}}</ref><ref name="CNN">{{Cite web|title=In quest for vaccine, US makes 'big bet' on company with unproven technology|url=https://edition.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html|accessdate=1 May 2020|author=Kuznia|date=1 May 2020|first=Robert|work=CNN Investigates|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154315/https://edition.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html|dead-url=no}}</ref>。

[[2019冠状病毒病|2019冠状病毒病]]莫德納[[莫德納疫苗|疫苗]]的[[奈米顆粒|奈米顆粒]]可將經人工合成的[[核苷酸|核苷酸]]修飾mRNA（稱為{{Link-en|modRNA|Nucleoside-modified messenger RNA}}）放入人體細胞中。然後，這種mRNA指揮[[細胞|細胞]]產生[[免疫反應|免疫反應]]。該技術平臺是一項新技術，此前由於將mRNA放入細胞時會產生[[副作用|副作用]]而被一度棄用<ref name=ST>{{cite web | url=https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | title=Ego, ambition, and turmoil: Inside one of biotech's most secretive startups | first=Damien | last=Garade | date=13 September 2016 | accessdate=18 May 2020 | website=[[Stat_(website)|Stat]] | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154313/https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | dead-url=no }}</ref><ref name=FT>{{cite newspaper | url=https://www.ft.com/content/ab138504-8c2e-11e7-a352-e46f43c5825d | title=Secretive Moderna yet to convince on $5bn valuation | first=David | last=Crow | date=6 September 2017 | accessdate=18 May 2020 | newspaper=[[Financial_Times|Financial Times]] | archive-date=2019-02-03 | archive-url=https://web.archive.org/web/20190203171135/https://www.ft.com/content/ab138504-8c2e-11e7-a352-e46f43c5825d | dead-url=no }}</ref><ref name=ST1>{{cite web | url=https://www.statnews.com/2017/01/10/moderna-trouble-mrna/ | title=Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine | first=Damien | last=Garde | website=[[Stat_(website)|Stat]] | date=10 January 2017 | accessdate=19 May 2020 | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154151/https://www.statnews.com/2017/01/10/moderna-trouble-mrna/ | dead-url=no }}</ref>。

== 歷史 ==
=== 技術儲備期（2010年 - 2016年） ===
2010年，[[幹細胞|幹細胞]]生物学家[[德里克·罗西|德里克·罗西]]为将自己的研究商业化，创建'''莫德納醫療'''（{{Lang|en|'''ModeRNA Therapeutics'''}}）<ref>{{cite news|author=Erin Kutz|title=ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells|url=http://www.xconomy.com/boston/2010/10/04/moderna-stealth-startup-backed-by-flagship-unveils-new-way-to-make-stem-cells/|work=Xconomy|date=4 October 2010|accessdate=2020-09-09|archive-date=2017-02-08|archive-url=https://web.archive.org/web/20170208132839/http://www.xconomy.com/boston/2010/10/04/moderna-stealth-startup-backed-by-flagship-unveils-new-way-to-make-stem-cells/|dead-url=no}}</ref><ref name="Xconomy20122">{{cite web|title=Moderna, $40M in Tow, Hopes to Reinvent Biotech with "Make Your Own Drug"|url=http://www.xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/|author=Gregory Huang|date=December 6, 2012|publisher=Xconomy|accessdate=2020-09-09|archive-date=2018-11-22|archive-url=https://web.archive.org/web/20181122092429/https://xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/|dead-url=no}}</ref>。莫德納意為[[信使核糖核酸|信使核糖核酸]]，即該公司的核心技術。

德里克·羅西開發了一種修飾mRNA的方法——首先將其[[轉染|轉染]]到人類細胞中，然後將其[[细胞分化|分化]]為幹細胞，然後再將其進一步分化為所需的[[靶細胞|靶細胞]]類型<ref>{{cite news|author=Erin Kutz|title=ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells|url=http://www.xconomy.com/boston/2010/10/04/moderna-stealth-startup-backed-by-flagship-unveils-new-way-to-make-stem-cells/|work=Xconomy|date=4 October 2010|access-date=7 February 2017|archive-date=2017-02-08|archive-url=https://web.archive.org/web/20170208132839/http://www.xconomy.com/boston/2010/10/04/moderna-stealth-startup-backed-by-flagship-unveils-new-way-to-make-stem-cells/|dead-url=no}}</ref><ref name=Xconomy2012>{{cite web|author=Gregory Huang|date=December 6, 2012|title=Moderna, $40M in Tow, Hopes to Reinvent Biotech with "Make Your Own Drug"|publisher=Xconomy|url=http://www.xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/|access-date=June 21, 2013|archive-date=2018-11-22|archive-url=https://web.archive.org/web/20181122092429/https://xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/|dead-url=no}}</ref>。德里克·羅西向[[哈佛大學|哈佛大學]]的同僚{{link-en|史蒂芬·斯普林格|Tim Springer}}求助，後者向{{link-en|肯尼思·錢|Kenneth Chien}}、{{link-en|鮑勃·蘭格|Bob Langer}}和[[風險投資|風險投資]]公司Flagship Ventures尋求共同投資。<ref name=Xconomy2012/><ref name=EltonNext2013>{{cite web|url=http://www.bostonmagazine.com/health/article/2013/02/26/moderna-therapeutics-new-medical-technology/|author=Catherine Elton|date=March 2013|title=The NEXT Next Big Thing|publisher=Boston Magazine|accessdate=Dec 11, 2013|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154152/https://www.bostonmagazine.com/health/2013/02/26/moderna-therapeutics-new-medical-technology/|dead-url=no}}</ref> 

2011年，Flagship Ventures（現為Flagship Pioneering）的執行長{{link-en|努巴·阿費揚|Noubar Afeyan}}任命了歐洲製藥銷售和運營主管{{link-en|斯特凡·班塞爾|Stéphane Bancel}}為執行長<ref name="ST" /><ref name=Xconomy2012/>。阿費揚個人擁有莫德納的19.5％的股份，是最大的單一股東，而他的基金旗艦創業公司則擁有18％<ref name=biospace>{{cite web | url=https://www.biospace.com/article/moderna-increases-ipo-goal-to-600-million/ | first=Mark | last=Terry | date=29 November 2018 | accessdate=19 May 2020 | website=BioSpace | title=Can Moderna Live up to the Hype? mRNA Company Increases IPO Goal to $600 Million | quote=The filings with the U.S. Securities and Exchange Commission (SEC) not only updated the proposed IPO but disclosed the size of the company's largest investors' stakes. Noubar B. Afeyan, company chairman, holds 19.5 percent, or 58,882,696 shares. Flagship Pioneering holds 18 percent of Moderna shares | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154257/https://www.biospace.com/article/moderna-increases-ipo-goal-to-600-million/ | dead-url=no }}</ref>。

2013年3月，莫德納與[[阿斯利康|阿斯利康]]簽署了一項為期五年的獨家選擇權協議，以發現、開發和商業化mRNA，將其應用於在[[心血管|心血管]]、[[代謝|代謝]]、[[腎臟疾病|腎臟疾病]]及特定[[癌症|癌症]]的治療領域。<ref name=ST/><ref name=York>{{cite web|author=Andrew Pollack|date=March 21, 2013|title=AstraZeneca Makes a Bet on an Untested Technique|work=The New York Times|accessdate=Dec 11, 2013|url=https://www.nytimes.com/2013/03/21/business/astrazeneca-to-pay-240-million-to-moderna-therapeutics.html|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154310/https://www.nytimes.com/2013/03/21/business/astrazeneca-to-pay-240-million-to-moderna-therapeutics.html|dead-url=no}}</ref><ref name=Globe>{{cite web|author=Robert Weisman|date=March 21, 2013|title=Moderna in line for $240m licensing deal|work=The Boston Globe|accessdate=Dec 11, 2013|url=https://www.bostonglobe.com/business/2013/03/20/moderna-therapeutics-receive-million-license-its-technology-drug-giant-astrazeneca/VAFlMn2lZaCDZ6A0oyHKSI/story.html|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154149/https://www.bostonglobe.com/business/2013/03/20/moderna-therapeutics-receive-million-license-its-technology-drug-giant-astrazeneca/VAFlMn2lZaCDZ6A0oyHKSI/story.html|dead-url=no}}</ref>根據協議，阿斯利康須向莫德納支付2.4億美元的預付款，且須購入莫德納8%的股份。<ref name=biospace/>截至2020年5月，只有代號為AZD8601的用於[[心肌缺血|心肌缺血]]治療的候選mRNA通過了[[臨床I期試驗|臨床I期試驗]]。<ref>{{cite web | url=https://www.pharmaceutical-technology.com/features/moderna-ipo-mrna/ | title=Moderna's gamble: what's behind biotech's biggest-ever IPO? | website=Pharmaceutical Technology | date=2019-02-21 | accessdate=2020-05-20 | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154149/https://www.pharmaceutical-technology.com/features/moderna-ipo-mrna/ | dead-url=no }}</ref><ref>{{cite web | url=https://www.modernatx.com/pipeline | title=Our Pipeline | accessdate=2020-05-19 | website=Modena | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154150/https://www.modernatx.com/pipeline | dead-url=no }}</ref>

2014年1月，莫德納和[[瑞頌製藥|瑞頌製藥]]簽署了一項價值1.25億美元的協議，用於急需治療方法的[[罕見病|罕見病]]。瑞頌向莫德納支付了1億美元，購買後者的mRNA治療平台的10個產品開發期權，用於治療包括[[克果納傑氏症|克果納傑氏症]]在內的罕見病。<ref name="reidy">{{cite news|author=Chris Reidy|url=https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics|title=Alexion, Moderna announce agreement to develop messenger RNA therapeutics|work=The Boston Globe|date=January 13, 2014|accessdate=March 18, 2020|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154209/https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics|dead-url=no}}</ref>
到2016年，斯特凡·班塞爾告訴[[摩根大通|摩根大通]]的投資者，與瑞頌製藥的合作將很快進入人體試驗階段。但是，到了2017年，該項目已被取消，因為動物實驗表明莫德納的治療方法永遠不可能達到足以用於人類的安全水平。<ref name=ST/><ref name=ST1/>

2014年，在令人失望的獨立治療性試驗之後，莫德納轉而著眼於[[mRNA疫苗|mRNA疫苗]]，因為除了[[療效|療效]]問題之外，mRNA總是會刺激受試者體內產生抗體。<ref name=CNN/><ref name=ST1/>鑑於疫苗開發的利潤空間較低，<ref name=CNN/>一些資深員工和行業專家對公司的未來生存能力提出質疑。<ref name=CNN/><ref name=ST1/>德里克·羅西離開了公司。<ref name=CNN/>

2016年2月，《[[自然_(期刊)|自然]]》雜誌的一篇[[社論對頁版|社論對頁版]]批評莫德納與大多數其他新興和成熟的生物技術公司迥異，從不發表任何關於其技術的經同行評議的論文，並將其與極富爭議的{{link-en|塞若納斯|Theranos}}相提並論。<ref name=Nature>{{cite journal | url=https://www.nature.com/articles/nbt.3488 | title=Research not fit to print | date=5 February 2016 | journal=[[自然_(期刊)|Nature]] | accessdate=19 May 2020 | volume=34 | issue=115 | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154214/https://www.nature.com/articles/nbt.3488 | dead-url=no }}</ref>

=== 上市期（2018年 - 2020年） ===
在2018年，公司更名為'''莫德納公司'''（{{Lang|en|'''Moderna Inc.'''}}），並進一步增加了疫苗開發項目。<ref name="CNN" /> 2018年12月，莫德納在[[納斯達克|納斯達克]]上市，創造了[[首次公開募股|首次公開募股]]，以每股23美元價格發行了2700萬股，共募集6.21億美元，其規模為生物技術領域的歷史之最。這也意味著整個公司的整體估值為75億美元。<ref name="for">{{cite magazine | url=https://fortune.com/2018/12/08/moderna-ipo-biotech-future/ | accessdate=18 May 2020 | date=8 December 2018 | first=Sy | last=Mukherjee | magazine=[[Fortune_(magazine)|Fortune]] | title=Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154242/https://fortune.com/2018/12/08/moderna-ipo-biotech-future/ | dead-url=no }}</ref><ref>{{cite web | url=https://www.businessinsider.com/biotech-moderna-prices-initial-public-offering-2018-12?r=US&IR=T | title=Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion | first=Lydia | last=Ramsey | date=7 December 2018 | website=[[Business_Insider|Business Insider]] | access-date=18 May 2020 | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154155/https://www.businessinsider.com/biotech-moderna-prices-initial-public-offering-2018-12?r=US&IR=T | dead-url=no }}</ref>
2019年[[美國證監會|美國證監會]]的年終文件顯示，自成立以來，莫德納累計虧損15億美元，僅2019年就虧損5.14億美元，自2010年以來籌集了32億美元的股權。<ref name="CNN" /><ref name="biospace" />截至2020年12月，莫德納的估值為600億美元。<ref name="yahoo12-4">{{cite web |title=Moderna stock price and market value |url=https://finance.yahoo.com/quote/MRNA?p=MRNA |publisher=Yahoo Finance |access-date=4 December 2020 |date=4 December 2020 |archive-date=2021-04-18 |archive-url=https://web.archive.org/web/20210418044846/https://finance.yahoo.com/quote/MRNA?p=MRNA |dead-url=no }}</ref>

2020年3月，在[[唐納·川普|特朗普]]政府與[[製藥業|製藥業]]高管之間的[[白宮|白宮]]會議上，班塞爾稱莫德納可以在幾個月內拿出[[2019冠狀病毒病|2019冠狀病毒病]]疫苗。<ref name=CNN/>次日，[[美國食品藥品監督管理局|美國食品藥品監督管理局]]（FDA）批准了莫德納候選疫苗的[[臨床試驗|臨床試驗]]，隨後莫德納獲得了[[曲速行動|曲速行動]]提供的4.83億美元投資。<ref name=CNN/>莫德納董事會成員{{link-en|蒙瑟夫·斯勞宜|Moncef Slaoui}}被任命為曲速行動的首席科學家。<ref name=CNN/>

=== 後疫情時代（2021年 - ）===
2021年8月，其[[呼吸道合胞病毒疫苗|人类呼吸道合胞病毒疫苗]] (mRNA-1345)获得[[美国食品药品监督管理局|美国食品药品监督管理局]])(FDA){{link-en|快速通道指定|Fast track (FDA)}}
<ref>{{Cite web|title=Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345), BUSINESS WIRE, August 3 2021|url=https://www.businesswire.com/news/home/20210803005702/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345}}</ref>。Moderna还研发针对[[流感|流感]]、COVID 和 [[人类呼吸道合胞病毒|人类呼吸道合胞病毒]]（RSV） 的三联疫苗<ref>{{Cite web|title=Phil Taylor, Moderna plans triple vaccine targeting flu, COVID and RSV, pharmaphorum, July 8, 2021|url=https://pharmaphorum.com/news/moderna-plans-triple-vaccine-targeting-flu-covid-and-rsv}}</ref>。

== 2019冠狀病毒病疫苗 ==
[[File:Moderna_COVID-19_vaccine.jpg|thumb]]
{{主条目|莫德納COVID‑19疫苗}}
=== 設計及臨床I至II期試驗 ===
2020年1月，莫德納宣佈將會開發一款能夠誘發針對[[SARS-CoV-2|SARS-CoV-2]]的免疫力的[[RNA疫苗|RNA疫苗]]mRNA-1273<ref>{{Cite news|url=https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8|title=With Wuhan virus genetic code in hand, scientists begin work on a vaccine|last1=Steenhuysen|first1=Julie|last2=Kelland|first2=Kate|date=2020-01-24|work=Reuters|access-date=2020-01-26|language=en|archive-date=2020-01-25|archive-url=https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8|dead-url=no}}</ref><ref name="carey">{{cite web |author1=Karen Carey |title=Increasing number of biopharma drugs target COVID-19 as virus spreads |url=https://www.bioworld.com/articles/433331-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads |publisher=BioWorld |accessdate=1 March 2020 |date=February 26, 2020 |archive-date=2020-02-27 |archive-url=https://web.archive.org/web/20200227150718/https://www.bioworld.com/articles/433331-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads |dead-url=no }}</ref><ref name="everett">{{cite web |author1=Gwen Everett |title=These 5 drug developers have jumped this week on hopes they can provide a coronavirus treatment |url=https://markets.businessinsider.com/news/stocks/drug-stocks-gain-companies-coronavirus-vaccine-potential-wall-street-buys-2020-2-1028947495 |publisher=Markets Insider |accessdate=1 March 2020 |date=February 27, 2020 |archive-date=2020-11-16 |archive-url=https://web.archive.org/web/20201116154220/https://markets.businessinsider.com/news/stocks/drug-stocks-gain-companies-coronavirus-vaccine-potential-wall-street-buys-2020-2-1028947495 |dead-url=no }}</ref>。mRNA-1273能夠通過編碼天然存在於SARS-CoV-2表面的預融合穩定刺突（S）蛋白來誘導對SARS-CoV-2的免疫力<ref>{{cite web | url=https://www.bloomberg.com/news/articles/2020-05-18/mit-professor-s-moderna-stake-on-the-brink-of-topping-1-billion | title=MIT Professor's Moderna Stake on the Brink of Topping $1 Billion | first1=Devon | last1=Pendleton | first2=Tom | last2=Maloney | website=[[Bloomberg_News|Bloomberg News]] | date=18 May 2020 | accessdate=18 May 2020 | quote=CEO Bancel, other Moderna executives have been selling shares | archive-date=2020-11-16 | archive-url=https://web.archive.org/web/20201116154212/https://www.bloomberg.com/tosv2.html?vid=&uuid=4b5e1c30-2822-11eb-8345-8ffe775ec24d&url=L25ld3MvYXJ0aWNsZXMvMjAyMC0wNS0xOC9taXQtcHJvZmVzc29yLXMtbW9kZXJuYS1zdGFrZS1vbi10aGUtYnJpbmstb2YtdG9wcGluZy0xLWJpbGxpb24= | dead-url=no }}</ref>。

2020年3月，mRNA-1273的[[臨床I期|臨床I期]]人體試驗開始，[[美國國家過敏和傳染病研究所|美國國家過敏和傳染病研究所]]為合作伙伴<ref>{{cite web |title=NIH clinical trial of investigational vaccine for COVID-19 begins |url=https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |website=National Institutes of Health (NIH) |accessdate=18 March 2020 |language=EN |date=16 March 2020 |archive-date=2020-03-19 |archive-url=https://web.archive.org/web/20200319120523/https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |dead-url=no }}</ref>。莫德納與[[瑞士|瑞士]]製藥商[[龍沙集團|龍沙集團]]簽訂合作協議，由後者提供每年3億劑的產能<ref>{{Cite web|url=https://www.swissinfo.ch/eng/sci-tech/swiss-factory-rushes-to-prepare-for-moderna-covid-19-vaccine/46081656|title=Swiss factory rushes to prepare for Moderna Covid-19 vaccine|website=SWI swissinfo.ch|access-date=2020-10-07|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154307/https://www.swissinfo.ch/eng/sci-tech/swiss-factory-rushes-to-prepare-for-moderna-covid-19-vaccine/46081656|dead-url=no}}</ref>。

2020年5月25日，莫德納開始[[臨床IIa期試驗|臨床IIa期試驗]]，共招募600位成年志願者測試疫苗的安全性和疫苗誘發的[[抗體|抗體]]水平差異<ref name="mod-04405076">{{ClinicalTrialsGov|NCT04405076|Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older}}</ref>。

2020年7月14日，莫德納的科學家發表了mRNA-1273的I期劑量遞增臨床試驗的初步結果。結果顯示，依劑量不同，最早於注射後第15天，針對S1和S2的中和抗體已被誘發。在所有劑量組中均觀察到輕度至中度的[[不良反應|不良反應]]，如[[發燒|發燒]]，乏力，頭痛，[[肌肉酸痛|肌肉酸痛]]和注射部位疼痛，在大劑量組中更為常見<ref name="jackson">{{cite journal |author1=Lisa A Jackson |author2=mRNA-1273 Study Group |title=An mRNA Vaccine against SARS-CoV-2 — Preliminary Report |journal=The New England Journal of Medicine |date=July 2020 |volume=383 |issue=20 |pages=1920–1931 |doi=10.1056/NEJMoa2022483 |pmid=32663912 |pmc=7377258}}</ref><ref>{{cite web|url=https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|title=Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus|author=Yun Li|publisher=[[CNBC|CNBC]]|date=July 14, 2020|accessdate=July 15, 2020|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154335/https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|dead-url=no}}</ref><ref name="jackson-app">{{cite journal |author1=Lisa A Jackson |author2=mRNA-1273 Study Group |title=Supplementary appendix for 'An mRNA Vaccine against SARS-CoV-2 — Preliminary Report' |journal=The New England Journal of Medicine |date=July 2020 |doi=10.1056/NEJMoa2022483 |pmid=32663912 |pmc=7377258 |url=https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf |access-date=2020-07-15 |archive-date=2020-07-14 |archive-url=https://web.archive.org/web/20200714224420/https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf |dead-url=no }}</ref>。低劑量的疫苗被認為是安全且有效的，可以進行相距29天的兩次100μg劑量的[[臨床III期試驗|臨床III期試驗]]<ref name="jackson" />。 

=== 臨床III期試驗 ===
莫德納和美國國家過敏和傳染病研究所於2020年7月27日在美國展開[[臨床III期試驗|臨床III期試驗]]，計劃招募3萬名志願者並將他們隨機分為兩組——一組注射兩劑100μg的mRNA-1273疫苗，另一組則注射[[安慰劑|安慰劑]]（0.9%的[[生理鹽水|生理鹽水]]）。<ref name="palca">{{cite news |last1=Palca |first1=Joe |title=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |accessdate=27 July 2020 |work=NPR |date=27 July 2020 |archive-date=2020-10-11 |archive-url=https://web.archive.org/web/20201011084836/https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people/ |dead-url=no }}</ref>

2020年11月16日，莫德納公佈其臨床III期試驗的初步數據，顯示mRNA-1273對預防感染[[2019冠狀病毒病|2019冠狀病毒病]]的效力達到94%<ref name="cnbc11-16">{{cite news |author1=Berkeley Lovelace, Jr. |author2=Noah Higgins-Dunn |title=Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar |url=https://www.cnbc.com/2020/11/16/moderna-says-its-coronavirus-vaccine-is-more-than-94percent-effective.html |accessdate=17 November 2020 |work=CNBC |date=16 November 2020 |archive-date=2020-11-16 |archive-url=https://web.archive.org/web/20201116154305/https://www.cnbc.com/2020/11/16/moderna-says-its-coronavirus-vaccine-is-more-than-94percent-effective.html |dead-url=no }}</ref><ref name="NYT-20201120">{{cite news |last=Zimmer |first=Carl |authorlink=Carl Zimmer |title=2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works. |url=https://www.nytimes.com/2020/11/20/health/covid-vaccine-95-effective.html |date=20 November 2020 |work=The New York Times |accessdate=21 November 2020 |archive-date=2020-11-22 |archive-url=https://web.archive.org/web/20201122231014/https://www.nytimes.com/2020/11/20/health/covid-vaccine-95-effective.html |dead-url=no }}</ref>，[[副作用|副作用]]則包括類似流感的症狀，如注射部位疼痛、乏力、[[肌肉痠痛|肌肉痠痛]]、頭痛等。<ref name=cnbc11-16/>這並非臨床試驗的最終結果，因為莫德納的臨床試驗計劃至2022年末方有正式結論。<ref name="NCT04470427">{{cite web |title=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427?term=moderna&cond=covid-19&draw=2&rank=1 |publisher=Clinicaltrials.gov, US National Library of Medicine |accessdate=17 November 2020 |date=28 October 2020 |archive-date=2021-02-25 |archive-url=https://web.archive.org/web/20210225192152/https://clinicaltrials.gov/ct2/show/NCT04470427?term=moderna&cond=COVID-19&draw=2&rank=1 |dead-url=no }}</ref>

莫德纳聲稱mRNA-1273疫苗在標準醫療冷櫃2--8°C（36--46°F）環境中，可儲藏至多30天；在零下20°C（−4°F）的環境中可儲藏至多4個月。<ref name=cnbc11-16/>

=== 緊急使用授權 ===
2020年11月30日，莫德纳公司宣布将于当日向[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）申请该疫苗的[[緊急使用授權|緊急使用授權]]（EUA），并向[[欧洲药品管理局|欧盟药品管理局]]等全球多家监管机构提交了滚动申请。莫德纳表示到2020年底，该公司预计将在美国运送约2000万剂疫苗，2021年有望在全球生产5至10亿剂<ref>{{Cite web|title=Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization|url=https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/|accessdate=2020-12-02|author=|date=2020-11-30|format=|publisher=investors.modernatx.com|language=en|archiveurl=https://web.archive.org/web/20201202031827/https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/|archivedate=2020-12-02|dead-url=no}}</ref>。

2020年12月18日，美國食品藥品監督管理局（FDA）批准了mRNA-1273的緊急使用授權<ref name="nih-eua">{{cite news |title=Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine |access-date=19 December 2020 |agency=US National Institutes of Health |date=18 December 2020 |archive-date=2021-03-19 |archive-url=https://web.archive.org/web/20210319122310/https://www.nih.gov/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine |dead-url=no }}</ref><ref>{{Cite web|last=Jr|first=Berkeley Lovelace|date=2020-12-19|title=FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution|url=https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html|access-date=2020-12-19|website=CNBC|language=en|archive-date=2021-01-26|archive-url=https://web.archive.org/web/20210126193134/https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html|dead-url=no}}</ref>。這也是莫德納第一款獲得FDA批准的產品。<ref>{{Cite web|last=Lee|first=Jaimy|title=Moderna nears its first-ever FDA authorization, for its COVID-19 vaccine|url=https://www.marketwatch.com/story/moderna-nears-its-first-ever-fda-authorization-for-its-covid-19-vaccine-11608134670|access-date=2020-12-19|website=MarketWatch|language=en-US|archive-date=2021-04-16|archive-url=https://web.archive.org/web/20210416034007/https://www.marketwatch.com/story/moderna-nears-its-first-ever-fda-authorization-for-its-covid-19-vaccine-11608134670|dead-url=no}}</ref>

== 參見 ==
* [[2019冠状病毒病阴谋论#莫德纳公司制造论|2019冠状病毒病阴谋论 § 莫德纳公司制造论]]
* [[RNA疫苗|RNA疫苗]]
* [[莫德纳2019冠状病毒病疫苗|莫德纳2019冠状病毒病疫苗]] (代号：mRNA-1273，商品名：Spikevax)
* [[BNT162|BNT162]]，由[[輝瑞製藥|輝瑞製藥]]與[[BioNTech|BioNTech]]聯合研製的2019冠狀病毒病疫苗
* [[呼吸道合胞病毒疫苗|呼吸道合胞病毒疫苗]]

== 参考文献 ==
{{Reflist|2}}

== 外部链接 ==
* {{official|https://www.modernatx.com}}
* {{Finance links
| name = Moderna, Inc.
| symbol = MRNA
| reuters = MRNA.O
| bloomberg = MRNA:US
| sec_cik = MRNA
| yahoo = MRNA
| google = MRNA
}}
{{authority control}}
[[Category:医学研究|Category:医学研究]]
[[Category:2010年成立的公司|Category:2010年成立的公司]]
[[Category:疫苗公司|Category:疫苗公司]]
[[Category:2018年首次公開募股|Category:2018年首次公開募股]]
[[Category:美国生物技术公司|Category:美国生物技术公司]]
[[Category:總部在美國的跨國公司|Category:總部在美國的跨國公司]]
[[Category:罕用药公司|Category:罕用药公司]] 
[[Category:美国制药公司|Category:美国制药公司]]
[[Category:納斯達克100指數成分股|Category:納斯達克100指數成分股]]
[[Category:財富500強公司|Category:財富500強公司]]